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To evaluate the effects of weight loss on the risk of having metabolic syndrome after 1 year of treatment 
with lifestyle modification alone, pharmacotherapy alone (sibutramine) or the combination of the two. 
Design: 
Randomized, controlled, 1-year clinical trial. 
Patients: 
One hundred and eighty women and 44 men, 18–65 years of age, with a body mass index of 30–45 kg/m2, 
free of uncontrolled hypertension or type 1 or 2 diabetes. 
Intervention: 
Fifteen milligrams of sibutramine per day alone, lifestyle modification counseling alone, sibutramine plus 
lifestyle modification counseling or sibutramine plus brief lifestyle modification counseling. 
Measurements: 
The metabolic syndrome, as defined by the Adult Treatment Panel III. 
Results: 
Before treatment, 34.8% of the participants had the metabolic syndrome. Metabolic syndrome was more 
prevalent in Caucasians than African Americans (42.5 vs 20.3%; P<0.03), in males than females (65.1 vs 
34.9%; P<0.002) and in older (>44 years) than younger (≤44 years) participants (47.5 vs 20.8%; 
P<0.0001). After 1 year of treatment, a moderate decrease in weight (8.0 ± 8.7 kg) resulted in significant 
reductions in the prevalence of metabolic syndrome from 34.8 to 27.2% of all participants (P<0.02). 
Logistic regression analyses indicated that for each 1 kg of weight lost, the odds of metabolic syndrome 
were reduced by 8% (CI=0.89–0.97; P<0.003). Lifestyle modification either alone (P<0.04), or in 
combination with sibutramine (P<0.05), significantly reduced the prevalence of metabolic syndrome 
compared with sibutramine alone. The group effect was removed after controlling for weight loss. 
Conclusions: 
The metabolic syndrome was prevalent in over one-third of obese individuals who sought weight loss 
treatment, and the prevalence differed by age, sex and ethnicity. Moderate weight loss markedly reduced 
the odds of metabolic syndrome in this sample. 
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Introduction 
The metabolic syndrome is a major public health problem in the United States, affecting almost one-
fourth of the adult population.1 People who have this syndrome are at increased risk for developing type 2 
diabetes and cardiovascular disease.2, 3, 4, 5 Thus, finding ways to ameliorate metabolic syndrome and its 
comorbidities is critical. 
Weight loss is associated with improvement in cardiovascular disease risk factors and reduced risk of type 
2 diabetes and, along with physical activity, is recommended as the first line of treatment for metabolic 
syndrome.6 Short-term studies have shown that weight loss improves metabolic syndrome7, 8, 9, 10 and its 
individual components.11, 12 However, few long-term studies have been conducted. Orchard et al.13 found 
that a lifestyle intervention that produced a 7% weight loss reduced the prevalence of metabolic syndrome 
by 15.6% in participants followed for a mean of 3.2 years. However, the sample was restricted to 
individuals with impaired glucose tolerance and a body mass index (BMI) ≥24 kg/m2. Després et al.14 
found that a 7% weight loss achieved with lifestyle modification and rimonabant reduced the prevalence 
of metabolic syndrome by 52% after 1 year of treatment. However, the authors speculated that 
improvements in the syndrome were partially attributable to the effects of rimonabant alone, independent 
of those of weight loss. Other authors also have reported an effect of rimonabant on components of the 
metabolic syndrome independent of weight loss.15, 16 
The present study examined the effect of weight loss on 1-year prevalence of metabolic syndrome in 
obese patients who received lifestyle modification alone, pharmacotherapy alone (sibutramine) or the 
combination of the two. We predicted that greater weight loss, achieved by lifestyle modification alone, 




Participants were 180 women and 44 men (N=224) who participated in a 1-year randomized controlled 
trial of lifestyle modification and pharmacotherapy for obesity. The study's protocol and principal 
outcomes have been reported previously.17 As shown in Table 1, the majority of participants were 
Caucasian (65.2%); 30.9% were African-American. Participants had an average age of 43.6 ± 10.2 years, 
weight of 107.0 ± 17.2 kg and BMI of 37.8 ± 4.2 kg/m2. Main inclusion criteria were an age of 18–65 
years and BMI of 30–45 kg/m2. Principal exclusion criteria were types 1 or 2 diabetes (as judged by the 
participants' primary care physicians); uncontrolled hypertension (>140/90 mm Hg); cerebrovascular, 
cardiovascular, kidney, or liver disease; pregnancy or lactation; the use of medications known to affect 
body weight; and major psychiatric disorders. 
Treatment 
The 224 participants were randomly assigned to one of four treatment conditions: (1) sibutramine alone; 
(2) group lifestyle modification alone; (3) sibutramine plus group lifestyle modification (i.e., combined 
therapy); or (4) sibutramine plus brief practitioner-delivered lifestyle modification (i.e., drug plus brief 
therapy). As described previously,17 the first treatment consisted of sibutramine alone (15 mg/day), which 
was monitored by a primary care provider at weeks 1, 3, 6, 10, 18, 26, 40 and 52. Lifestyle modification 
alone consisted of weekly group meetings from weeks 1–18, biweekly sessions from weeks 20–40, and a 
follow-up visit at week 52. Combined therapy provided the combination of sibutramine and group 
lifestyle modification. Sibutramine plus brief therapy consisted of 10–15 min visits with a primary care 
provider at weeks 1, 3, 6, 10, 18, 26, 40, and 52. During these visits, medication was monitored, and 
participants also received two treatment manuals18, 19 and instruction in completing food and activity 
records (as did participants in the two group lifestyle modification conditions). 
Thirty-nine participants (17.4%) did not complete the 1-year study. This number includes any individual 
who attended the first treatment visit and did not return. There were no significant differences in attrition 
among the four treatment groups, as described previously.17 Written informed consent was obtained from 
all participants, and this study was approved by the University of Pennsylvania's institutional review 
board. This research was supported by grants DK56124 and DK065018 from the National Institutes of 
Diabetes, Digestive and Kidney Disease. Abbott Laboratories provided the medication used in the study. 
Measures 
Weight 
Weight was measured at all treatment visits and at baseline and weeks 18, 40 and 52 on a digital scale 
(Detecto, model 6800), with participants dressed in light clothing without shoes. 
Serum chemistries 
Blood samples were drawn at baseline and weeks 18, 40 and 52 following an overnight fast. 
Triglycerides, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein (HDL) 
cholesterol, insulin and glucose were measured (Quest Diagnostics, Horsham, PA, USA). Insulin 
sensitivity was estimated by the homeostasis model of insulin sensitivity (HOMA).20 
Blood pressure and pulse 
Blood pressure and pulse were measured by research assistants using a Dinamap monitor (Johnson & 
Johnson, XL model 9300). Two readings were taken at 1-min intervals after participants had been seated 
for ≥ 5 min. Measurements were obtained at all treatment visits, as well as at baseline and weeks 18, 40 
and 52. 
Definition of the metabolic syndrome 
Metabolic syndrome was defined according to criteria from the National Cholesterol Education Program's 
Adult Treatment Panel III,6 which requires that three or more of the following conditions be met: (1) 
waist circumference greater than 102 cm in men and 88 cm in women; (2) serum triglyceride level of at 
least 1.7 mmol/l (≥150 mg/dl); (3) HDL cholesterol level less than 1.03 mmol/l (<40 mg/dl) in men and 
less than 1.3 mmol/l (<50 mg/dl) in women; (4) blood pressure of at least 130 mm Hg systolic or 85 mm 
Hg diastolic; and (5) fasting plasma glucose level of 6.2 mmol/l (110 mg/dl). Participants who were being 
treated with blood pressure or triglyceride-lowering medications were classified as positive for the 
respective criterion. We chose the ATP III criteria for their clinical utility and to be consistent with other 
studies.13, 14 
Statistics 
Logistic regression analyses were used to examine differences in prevalence of metabolic syndrome at 
baseline and week 52. At baseline, analyses examined the prevalence of metabolic syndrome across 
different age, ethnicity and gender categories. At week 52, analyses examined the prevalence of metabolic 
syndrome after adjusting for baseline prevalence of the syndrome, group, age, ethnicity and gender. 
Logistic regression analyses also were used to examine group differences in prevalence of metabolic 
syndrome, adjusting for ethnicity, age and gender. Weight was later entered as an additional covariate in 
the analyses. 
There were no significant differences between groups in baseline demographic variables or in the 
prevalence of metabolic syndrome. χ2 analyses were used to examine group differences after 1 year of 
treatment in proportions of cases that developed the metabolic syndrome (i.e., did not meet criteria at 
baseline but did at the 1-year assessment) or resolved it (i.e., met criteria at baseline but not at the 1-year 
assessment). Similar analyses were used to examine 1-year group differences in the development and 
resolution of the components of the metabolic syndrome. Weight data were examined for all persons who 
began treatment using an intention-to-treat analysis in which participants who discontinued treatment 
were assumed to regain 0.3 kg/months after leaving the study.17 Data for the metabolic syndrome 
components were examined using a last-observation-carried forward (LOCF) analysis. 
Results 
Baseline prevalence of the metabolic syndrome 
Figure 1 shows that, before treatment, 34.8% of the participants met the criteria for the metabolic 
syndrome. The prevalence of the syndrome was significantly greater in Caucasians than African 
Americans (42.5 vs 20.3%; P<0.03), in males than females (65.1 vs 34.9%; P<0.002) and in older (>44 
years) than younger (≤ 44 years) participants (47.5 vs 20.8%; P<0.0001). The severity of metabolic 
syndrome, in terms of the number of the five criteria met at baseline (M=2.2 ± 1.0), did not differ 
significantly by age, ethnicity, or gender. Figure 1 also shows that, before treatment, 100% of participants 
had an elevated waist circumference, and 45.5% had high blood pressure. High HDL cholesterol, 
triglycerides and blood glucose followed in this order. 
Metabolic syndrome after weight loss 
Study participants (N=224) lost an average of 8.0 ± 8.7 kg (7.5 ± 7.9% of initial body weight) after 1 year 
of treatment. This weight loss was associated with a significant (P<0.02) reduction in the prevalence of 
metabolic syndrome, from 34.8 to 27.2% of participants. Logistic regression analyses indicated that for 
each 1 kg of weight lost, the odds of having metabolic syndrome at the 1-year assessment were reduced 
by 8% (CI=0.89–0.97; P<0.003), after adjusting for demographic variables, baseline metabolic syndrome 
status and treatment group. The relationship between weight loss and 1-year prevalence of metabolic 
syndrome appeared linear (point-biserial correlation=0.20, P<0.003). 
Participants who lost ≥5% of initial body weight had a 59.2% reduction in the odds of having metabolic 
syndrome compared with those losing <5% (CI=0.20–0.85; P<0.02). Participants who lost ≥10% of initial 
body weight had an 83.2% reduction in odds of having metabolic syndrome compared with those who 
lost <10% (CI=0.07–0.42; P<0.0001). 
Table 2 illustrates resolution and incidence rates of the metabolic syndrome and its components after 1 
year of treatment. Of the 78 participants who met the criteria for the syndrome at baseline, 46.2% no 
longer met them at the 1-year assessment. Only 13.0% of the 146 participants who did not meet criteria 
for metabolic syndrome at baseline developed the syndrome after the year of treatment. 
Changes in metabolic syndrome across treatment groups 
As reported previously,17 the combination of group lifestyle modification and sibutramine induced a loss 
of 11.0 ± 8.8% of initial weight at 1 year, which was significantly greater than that produced by 
sibutramine alone (4.7 ± 6.7%), lifestyle modification alone (6.7 ± 7.8%) and drug plus brief therapy (7.0 
± 7.7%). The latter three groups did not differ significantly from each other in weight loss at the 1-year 
assessment. 
Logistic regression analyses indicated that, compared with the sibutramine alone condition, lifestyle 
modification alone and combined therapy reduced the odds of having metabolic syndrome by 66.3% 
(P<0.04; CI=0.12–0.93) and 60.1% (P<0.05; CI=0.15–0.99), respectively, after adjusting for baseline 
metabolic syndrome status and demographic variables. No significant effect was found for the drug plus 
brief therapy group. When weight loss was entered as a covariate, all group differences in the 1-year odds 
of having metabolic syndrome were removed, suggesting that there was no effect of the separate 
treatments, independent of the weight loss associated with them. 
Table 3 shows that rates of resolving and developing metabolic syndrome across the four treatment 
groups at the 1-year assessment. The greatest number of cases of metabolic syndrome was resolved in the 
lifestyle modification alone (72.2%) and combined therapy (61.9%) groups, which did not differ 
significantly from each other. There were no significant differences in the development (i.e., incidence) of 
metabolic syndrome in the three groups that received sibutramine vs lifestyle modification alone (average 
of 10 vs 4%). 
Table 4 shows the 1-year prevalence rate of the metabolic syndrome, as well as rates of resolving or 
developing the components of the metabolic syndrome in the four treatment groups. There were no 
statistically significant differences across the groups in the resolution or development of hyperglycemia, 
low HDL cholesterol, or high waist circumference. As reported previously,17 there were also no 
statistically significant differences across the groups in 1-year changes in HOMA (which changed from 
4.8 ± 5.8 to 4.4 ± 5.9 in the sibutramine alone group, 3.9 ± 2.7 to 2.8 ± 2.1 in the lifestyle modification 
alone, 3.9 ± 2.2 to 2.8 ± 2.0 in combined therapy and 5.0 ± 4.5 to 3.9 ± 4.5 in the drug plus brief therapy 
group). However, the combined therapy and lifestyle modification alone groups appeared to reduce the 
prevalence of high blood pressure and high triglycerides to a greater extent than the sibutramine alone and 
drug plus brief therapy and groups. 
Given concerns that norepinephrine reuptake inhibition with sibutramine could exacerbate arterial 
hypertension, we compared the combined therapy and lifestyle modification alone groups on the rates of 
resolving and developing high blood pressure (i.e., ≥130/85 mm Hg). No significant differences were 
observed; 8.3% of persons in the combined therapy group and 7.7% of cases in the lifestyle modification 
groups developed high blood pressure over the 1-year study. Among participants who had high blood 
pressure at baseline, 50.0% of cases in the combined therapy group and 34.5% of cases in lifestyle 
modification alone group were resolved at the 1-year follow-up (Table 4). The combined therapy and 
lifestyle modification alone groups also did not significantly differ on any of the other metabolic 
syndrome components (Table 4). Analyses stratified by weight loss category (<5, 5–10 and >10% weight 
losses) revealed similar findings. 
Discussion 
The metabolic syndrome was prevalent in over one-third of obese individuals who sought weight loss 
treatment in this study, a value which is higher than the national average of 22% of American adults.1 
Given that the main components of metabolic syndrome are all associated with excess weight (i.e., waist 
circumference, blood pressure, glucose and lipid levels), the greater prevalence of the metabolic 
syndrome in our sample is not surprising. Moreover, it would have been even higher if we had not 
excluded persons with type 2 diabetes from this trial. (We note that participants' primary care physicians 
reported that participants were free of diabetes, but approximately 10% of our sample had a baseline 
fasting blood sugar level ≥126 mg/dl.) The prevalence of metabolic syndrome was greater among older 
participants, Caucasians and males in our sample. Similar findings have been reported elsewhere for age.1 
Findings on ethnicity21, 22 and gender1 have been equivocal. 
Lifestyle modification, either alone or in combination with sibutramine, reduced the prevalence of 
metabolic syndrome significantly. (The prevalence was affected by cases in which the syndrome either 
developed or resolved.) After 1 year of treatment, the prevalence of the metabolic syndrome declined by 
44% in the lifestyle modification alone group and 48% in the combined therapy group compared with a 
5% reduction in the sibutramine alone condition. Other studies have reported similar reductions in 
prevalence of metabolic syndrome after combined medication and lifestyle modification treatments. 
Despres et al.14 reported a 52% reduction in the prevalence of metabolic syndrome after 1 year of 
treatment with lifestyle modification and rimonabant 20 mg/day. Pi-Sunyer et al.15 reported a 40% 
reduction in the prevalence of metabolic syndrome after 1 year of treatment with rimonabant 20 mg/day 
and dietary counseling. 
Lifestyle modification, alone or in combination with sibutramine, had a dramatic effect on the resolution 
of metabolic syndrome. Among participants who had the syndrome at baseline, 72% of the lifestyle 
modification alone and 62% of combined therapy groups no longer had the syndrome after 1 year of 
treatment (compared with 37% of the sibutramine alone group). Resolution rates were not reported in the 
1-and 2-year studies of rimonobant.14, 15 However, the resolution rates in our study were higher than those 
observed after 3.2 years of lifestyle modification in participants with impaired glucose tolerance in the 
Diabetes Prevention Program (DPP), at which time 38% of participants who received the lifestyle 
intervention no longer had the syndrome.13 
Weight loss appeared to be the driving force behind the reductions in metabolic syndrome in our sample. 
After adjusting for weight loss, group differences in the 1-year prevalence of metabolic syndrome 
disappeared. In the sample as a whole, a loss of 5% or more of initial body weight reduced the odds of 
having metabolic syndrome by 59%. Similar findings have been reported elsewhere. In a sample of obese 
middle-aged men with a high prevalence (60%) of metabolic syndrome, Kukkonen-Harjula et al.23 found 
that a 4.8 kg weight loss reduced the odds of having metabolic syndrome by 71% at the end of a 2.5-year 
study. The authors reported similar findings in a study of women.24 
The lifestyle modification alone and combined therapy groups had comparable effects in reducing the 
prevalence of metabolic syndrome, despite the former group's losing less weight (6.7 ± 7.8 vs 11.0 ± 
8.8%, respectively). The reasons for this are unclear. Prior research has shown that sibutramine, despite 
inducing significantly more weight loss, did not improve glucose control significantly more than 
placebo.25 Similarly, in the current study the combined therapy and lifestyle modification alone groups 
did not differ significantly on changes in glucose or insulin sensitivity, as assessed by HOMA. The lack 
of significant differences between groups in the present study may reflect a lack of statistical power. In 
addition, we selected patients who were free of type 2 diabetes, thus, limiting the baseline glucose values 
(and the likelihood of observing clinically significant changes on this measure). Further study is needed of 
the potential independent effects of sibutramine on glycemic control. 
We note that in the current study the addition of sibutramine to lifestyle modification was associated with 
generally favorable effects on blood pressure. Abnormal blood pressure (i.e., 130/85 mm Hg) resolved in 
50.0% of participants in this condition, compared with 34.5% of participants in the lifestyle modification 
alone group. (The difference between groups was not statistically significant.) Thus, even though 
sibutramine may be associated with small mean increases in pulse and blood pressure,26, 27 small 
improvements in blood pressure may be observed in patients treated by 10 to 15 mg/day of sibutramine 
who lose approximately 10% of initial weight. However, as was the case with glycemic control, our main 
study was not designed (or powered) to compare differences in blood pressure between treatment groups. 
It is possible that participants in the lifestyle modification alone group adopted more favorable dietary 
(e.g., a lower carbohydrate intake) or physical activity habits,28 although we do not have adequate data to 
test those hypotheses. 
This study had several additional limitations. The sample sizes of our groups were small, which may have 
limited our power to detect significant group differences in the development or resolution of metabolic 
syndrome and its components. The population was limited to obese individuals who sought weight loss 
treatment at a university-based clinic, so the findings may not generalize to other populations. We used a 
LOCF analysis to examine changes in components of the metabolic syndrome, which may have inflated 
rates of resolution of metabolic syndrome. 
In conclusion, we found the metabolic syndrome was prevalent in over one third of obese individuals who 
sought weight loss treatment, and the prevalence differed by age, sex and ethnicity. Moderate weight loss 
markedly reduced the odds of having metabolic syndrome, underscoring the value of weight loss in the 
treatment of this condition. 









Female  80.4  62.8  89.7  0.0001 
Male  19.6  37.2  10.3    
              
Ethnicity (% subjects) 
White  65.2  79.5  57.9    
African‐American  30.9  17.9  37.9  0.005 
Hispanic  3.6  2.6  4.1    
              
Age (year)  43.6 ± 10.2  47.8 ± 9.9  41.4 ± 9.7  0.0001 
Weight (kg)  107.0 ± 17.2  111.2 ± 18.3  104.7 ± 16.2  0.007 
Height (cm)  167.9 ± 8.4  169.6 ± 9.4  167.0 ± 7.6  0.04 
BMI (kg/m2)  37.8 ± 4.2  38.4 ± 4.0  37.4 ± 4.3  0.07 
Systolic BP (mm Hg)  124.7 ± 14.7  133.4 ± 13.5  120.0 ± 13.1  0.0001 
Diastolic BP (mm Hg)  68.0 ± 9.8  72.5 ± 10.2  65.6 ± 8.7  0.0001 
Pulse (bpm)  78.6 ± 10.6  80.6 ± 10.8  77.6 ± 10.4  0.05 
Triglycerides (mg/dl)  131.1 ± 102.1  191.1 ± 137.8  97.3 ± 51.5  0.0001 
              
Cholesterol 
Total (mg/dl)  198.2 ± 33.9  200.5 ± 33.8  196.6 ± 33.9  0.42 
LDL‐C (mg/dl)  117.7 ± 29.6  117.9 ± 29.7  117.3 ± 29.6  0.87 
HDL‐C (mg/dl)  55.2 ± 14.3  46.4 ± 10.7  60.0 ± 13.7  0.0001 
              
Glucose (mg/dl)  95.2 ± 13.9  100.8 ± 13.7  91.8 ± 10.3  0.0001 
Insulin (muU/ml)  17.9 ± 13.4  22.6 ± 17.9  15.3 ± 9.4  0.001 
HOMA  4.7 ± 4.4  6.3 ± 6.2  3.8 ± 2.6  0.001 
Abbreviations: BMI, body mass index; HDL-C, high-density lipoprotein-cholesterol, HOMA, 
homeostasis model of insulin sensitivity, LDL-C, low-density lipoprotein-cholesterol. 
* P-values represent differences between participants with the metabolic syndrome vs those 
without the syndrome based on independent t-tests (for continuous variables) and χ2 test (for 
categorical variables). 
Note: Values presented are mean ± s.d.; b.p.m., beats per minute. 
 
Table 2: Percentage of participants (N=224) who, after 1 year of treatment, 











Metabolic syndrome 34.8 (N=78) 27.2 (N=61) 46.2 (N=36) 13.0 (N=19) 
Waist circumference 100 (N=224) 91.5 (N=205) 8.5 (N=19) 0 (N=0) 
Blood pressure 45.5 (N =102) 39.3 (N=88) 31.4 (N=32) 14.8 (N=18) 
HDL cholesterol 33.9 (N=76) 33.5 (N=75) 25.0 (N=19) 12.2 (N=18) 
Triglycerides 26.3 (N=59) 19.6 (N=44) 49.2 (N=29) 8.5 (N=14) 
Glucose 11.2 (N=25) 6.3 (N=14) 68.0 (N=17) 3.0 (N=6) 
 
 Abbreviation: HDL, high-density lipoprotein. 
 
 
Table 3: Percentage of participants in each group who resolved or developed metabolic syndrome (MS) after 











Baseline prevalence MS (%) 34.5a (N=19) 37.0a (N=20) 30.0a (N=18) 38.2a (N=21) 
1-year prevalence MS (%) 32.7a (N=18) 40.7a (N=22) 18.2b (N=10) 18.3b (N=11) 
% cases resolved MS 36.8a (N=7) 15.0a (N=3) 72.2b (N=13) 61.9b (N=13) 
% cases developed MS 16.7a (N=6) 14.7a (N=5) 5.4a (N=2) 15.4a (N=6) 
 
Across rows, values with different subscripts differ significantly based on χ2 tests, P<0.05. Participants in the sibutramine alone, sibutramine plus 
brief therapy, lifestyle modification alone, and combined therapy groups lost 4.7 ± 6.7, 7.0 ± 7.0, 6.7 ± 7.8, and 11.0 ± 8.8% of initial body weight, 
respectively.17 
 
Table 4: Percentage of participants in each group who resolved or developed 














 Baseline prevalence (%)  100a (N=55)  100a (N=54)  100a (N=55)  100a (N=60) 
 1‐year prevalence (%)  94.5a (N=52) 90.7a (N=49)  90.9a (N=50)  90.0a (N=54) 
 % cases resolved  5.5a (N=3)  9.3a (N=5)  9.1a (N=5)  10.0a (N=6) 
 % cases developed  0.0a (N=0)  0.0a (N=0)  0.0a (N=0)  0.0a (N=0) 
              
HDL 
 Baseline prevalence (%)  29.1a (N=16) 40.7a (N=22)  30.9a (N=17)  35.1a (N=21) 
 1‐year prevalence (%)  27.3a (N=15) 42.6a (N=23)  30.9a (N =17)  33.3a (N=20) 
 % cases resolved  25.0a (N=4)  22.3a (N=5)  23.5a (N=4)  47.6a (N=6) 
 % cases developed  7.7a (N=3)  18.8a (N=6)  10.5a (N=4)  12.8a (N=5) 
              
Blood pressure 
 Baseline prevalence (%)  52.7a (N=29) 37.0a (N=20)  52.7a (N=29)  40.0a (N=24) 
 1‐year prevalence (%)  49.1a (N=27) 46.3a (N=25)  38.2 b (N=21)  25.0ab (N =15) 
 % cases resolved  24.1a (N=7)  15.0a (N=3)  34.5a (N=10)  50.0a (N=12) 
 % cases developed  19.2a (N=5)  23.5a (N=8)  7.7a (N=2)  8.3a (N=3) 
              
Triglycerides 
 Baseline prevalence (%)  25.5a (N=14) 31.5a (N=17)  25.5a (N=14)  23.3a (N=14) 
 1‐year prevalence (%)  27.3a (N=15) 29.6a (N=16)  10.9b (N=6)  11.7b (N=7) 
 % cases resolved  42.9a (N=6)  23.5a (N=4)  57.1a (N=8)  78.6a (N=11) 
 % cases developed  17.1a (N=7)  8.1ab (N=3)  0.0b (N=0)  8.7ab (N=4) 
              
Glucose 
 Baseline prevalence (%)  10.9a (N=6)  18.5a (N=10)  10.9a (N=6)  5.0a (N=3) 
 1‐year prevalence (%)  9.1a (N=5)  9.3a (N=5)  3.6a (N=2)  3.3a (N=2) 
 % cases resolved  50.0a (N=3)  70.0a (N=7)  66.6a (N=4)  100a (N=3) 
 % cases developed  4.1a (N=2)  4.6a (N=2)  0a (N=0)  3.5a (N=2) 
 
 Across rows, values with different subscripts differ significantly based on χ2 tests, P<0.05. 
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